NCT02795429 - Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 15, 2016

Primary Completion Date

June 1, 2021

Study Completion Date

June 24, 2021

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG

Spartalizumab

Spartalizumab administered via intravenous (i.v.) infusion once every 3 weeks (Q3W)

DRUG

Capmatinib

Capmatinib administered orally as a tablet on a continuous twice daily (BID) dosing schedule

Trial Locations (17)

10002

Novartis Investigative Site, Taipei

20089

Novartis Investigative Site, Rozzano

20132

Novartis Investigative Site, Milan

31059

Novartis Investigative Site, Toulouse

34059

Novartis Investigative Site, Montpellier

41124

Novartis Investigative Site, Modena

59037

Novartis Investigative Site, Lille

69120

Novartis Investigative Site, Heidelberg

70403

Novartis Investigative Site, Tainan City

97080

Novartis Investigative Site, Würzburg

200032

Novartis Investigative Site, Shanghai

510515

Novartis Investigative Site, Guangzhou

M5G 2M9

Novartis Investigative Site, Toronto

H3T 1E2

Novartis Investigative Site, Montreal

Unknown

Novartis Investigative Site, Hong Kong

03080

Novartis Investigative Site, Seoul

03722

Novartis Investigative Site, Seoul